ASPO Abstracts

Acute cancer-related symptoms and concerns among patients receiving chemotherapy in the current treatment landscape

Authors: Smith KS, Hoogland AI, Welniak T, Nguyen L, Rodriguez Y, Li X, Oswald LB, Carpenter KM, Fischer SM, Li D, Kinney AY, Gonzalez BD, Jim HSL

Category: Survivorship & Health Outcomes/Comparative Effectiveness Research
Conference Year: 2023

Abstract Body:
Purpose: Symptom prevalence and severity among patients treated with emetogenic chemotherapy have been well-documented; however, this literature is ten or more years old and does not reflect current treatment regimens. The current study assesses the prevalence of acute cancer-related symptoms and health concerns 5 days after initiation of moderately- or highly-emetogenic chemotherapy, when symptoms are expected to be most pronounced. Methods: Cancer patients scheduled for chemotherapy were recruited to a large, multi-site observational study. Participants completed questionnaires on sociodemographics, cancer-related symptoms, and quality of life (QOL) concerns. Clinical data were abstracted via medical record review. Symptoms were evaluated using the Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Symptoms were considered severe when participants responded "severe

Keywords: chemotherapy-induced nausea, patient reported outcomes, quality of life, emetogenic chemotherapy